BioSig Technologies, Inc. (BSGM)

Home

PURE EP™ System

More information, better decisions

The PURE EP™ System sets a new standard in electrophysiology by providing essential intracardiac signals with high clinical value in all types of cardiac ablations.

Learn More About PURE EP™Learn More From the Users

Now combining the best-in-class intracardiac signal acquisition technology with the new PURE EP™ Software Version 4 designed around 4 key procedural steps.

More than 1,100 patient cases have been conducted using the PURE EP™ System by 53 physicians in twelve clinical sites to date.

BioSig to Host Conference Call to Unblind Clinical Data Collected with PURE EP™

BioSig will host a call at 2:30 PM (ET) on Monday, July 26, 2021, to discuss the recent conclusions of its PURE EP(tm) 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA.

Press ReleaseJuly 12, 2021

BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology

Previously the Company increased the patient case goal from 1000 to at least 1500 procedures by the end of 2021, having delivered 425 procedures at the end of 2020. The Company is currently conducting patient cases in nine medical centers across the country.

Press ReleaseJune 30, 2021

PURE EP™ To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat

Presentation to highlight clinical applications of the Company’s latest software for arrhythmia care. Mr. Olivier Chaudoir, BioSig’s Senior Director of Marketing, will demonstrate the applications of the newest software features of the Company’s PURE EP(tm) System in clinical practice.

Press ReleaseJune 28, 2021

PURE EP™ to be Featured in Two Clinical and Scientific Presentations during Heart Rhythm 2021 convention

Abstracts are due to be presented by physician users and research investigators from two leading institutions. The annual Heart Rhythm 2021 convention takes place on July 28-31, 2021, at the Boston Convention and Exhibition Center in Boston, MA. The Company will be exhibiting at booth 849.

Press ReleaseJune 22, 2021

Bioelectronic Medicine:
The Leading Edge of Healthcare

Bioelectronic medicine is a new, rapidly growing field of healthcare that explores how targeted electrical signals in the body can help to diagnose and treat a wide range of diseases, from diabetes to depression.
BioSig aims to play a vital role in the field of bioelectronic medicine, based on our unique enabling technology and core competency in signal processing. Our initial focus is on heart disease and the fast-growing electrophysiology device market.

What Is Bioelectronic Medicine?

The Need to Improve Arrhythmia Treatment

Heart Disease Is the
#1 Cause of Death

Arrhythmia, a common cardiac condition, causes the heart to beat too quickly, too slowly, or erratically. New signal processing technologies could play a key role in enhancing outcomes from one of the most important treatments for arrhythmia: catheter ablation.

Challenging, Costly Conditions

The health and economic impacts of arrythmia are immense. The most common arrhythmia, atrial fibrillation (AFib), affects 33 million people worldwide* – generating annual healthcare costs of $15,000 to $25,000 per patient*.

*Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; “Healthcare Costs Drop Sharply after Successful Ablation,” Marlene Busko, Medscape, May 4, 2016

Barriers to Treatment Efficacy

Treatment of AFib and ventricular tachycardia typically starts with drug therapy, which is often ineffective, particularly in the later stages of heart disease. Catheter ablation often fails, leading to costly repeat procedures.

The Importance of Signal Clarity

Clearer signal information may help physicians work faster and more accurately during catheter ablation. One of the main reasons for low ablation success rates is unreliable information – specifically, the inability to differentiate between the clean signal and lab noise.

PURE EP™: A Signal Processing Solution

By improving signal clarity, BioSig’s PURE EP™ System has the potential to deliver valuable advances in electrophysiology procedures. We recently conducted first clinical cases at the Texas Cardiac Arrhythmia Institute under the leadership of Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. According to Dr. Natale, early results suggested improved cardiac signal detection and fidelity - click here to read the announcement.

How Does Pure EP™ Work?

Key Scientific Publications

We’re proud of our high success rate for peer-reviewed publications: 9 of the 10 publications we’ve submitted to date have been accepted. These publications provide early evidence that PURE EP™ could offer valuable improvements in signal clarity during electrophysiology procedures.

Browse Our Publications

Looking Beyond Arrhythmia

In 2017, BioSig signed a 10-year strategic collaboration with experts at Mayo Clinic to jointly develop our signal processing technology. These experts see the potential for our technology to help them electrically map the entire body, possibly leading to diagnosis and development of new therapies in other disease areas – for example, neurology and ophthalmology.

Learn About Our Partnerships

Creating Value for Investors

BioSig is a NASDAQ-traded company with a clear path to commercialization and growth, proven credentials for success, and a world-class leadership team. Check out our Investor Resources for financial and governance information, stock performance, SEC filings, and other materials.

See Investor Resources